E-Mail
IMAGE: Sumit Chanda, co-senior study author and director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys. view more
Credit: Sanford Burnham Prebys Medical Discovery Institute
LA JOLLA, CALIF. - March 16, 2021 - A
Nature study authored by scientists at Sanford Burnham Prebys Medical Discovery Institute and the University of Hong Kong shows that the leprosy drug clofazimine, which is FDA approved and on the World Health Organization s List of Essential Medicines, exhibits potent antiviral activities against SARS-CoV-2 and prevents the exaggerated inflammatory response associated with severe COVID-19. Based on these findings, a Phase 2 study evaluating clofazimine as an at-home treatment for COVID-19 could begin immediately.